PDF herunterladen
Horm Metab Res 2017; 49(08): 589-594
DOI: 10.1055/s-0043-113573
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Impaired Metabolism of Selenomethionine in Graves’ Disease: A Biokinetics Study of Soft Gel Capsule Formulation

Leonidas H. Duntas
1   Evgenideion Hospital, Unit of Endocrinology, Diabetes and Metabolism, University of Athens, Athens, Greece
,
Anastasios Boutsiadis
1   Evgenideion Hospital, Unit of Endocrinology, Diabetes and Metabolism, University of Athens, Athens, Greece
,
Athanasios Tsakris
2   Evgenideion Hospital, Unit of Medical Biopathology, Department of Microbiology, University of Athens, Athens, Greece
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 11. April 2017

accepted 08. Juni 2017

Publikationsdatum:
05. Juli 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Patients with Graves’ disease are known to have low selenium (Se) status, Se supplementation resulting in clinical and biochemical improvement. Selenomethionine (SeMet) in a new soft gel capsule formulation was used in a pilot study in 6 patients with acute Graves’ disease and low selenium levels (61.3±12.9 μg/l) before and in 4/6 patients 3 months after combined treatment with methimazole and SeMet 200 μg/day (113.3±46.3 μg/l), as well as in 6 euthyroid controls (82±11.8 μg/l). The biokinetics were studied following ingestion of 200 μg SeMet (single dose) soft gel capsule, Se serum concentrations being measured at various time points within 24 h. Se levels rose variably in all patients and controls. While levels peaked in all subjects following 8 h of intake, the increase was somewhat slower in acute hyperthyroidism as compared to 3 months later when these patients had been rendered euthyroid, this possibly due to derangement of Se storage capacity by SEPP or increased requirements in the acute phase of the disease, leading to depletion of the trace element. The compound was shown to be bioavailable and safe and patients treated for 3 months exhibited higher Se levels at the different time points. These findings are of major importance for sufferers of GD since they indicate that early Se supplementation, with its beneficial antioxidant impact on inflammatory activity, could slow, or possibly even forestall, the clinical progression of the disease.

Key words

selenium - selenomethionine - selenium biokinetics - Graves’ disease - hyperthyroidism - selenium soft gel capsule
 

  • References

  • 1 Weetman AP. Graves’ disease. N Engl J Med 2000; 343: 1236-1248
    CrossrefPubMedGoogle Scholar
  • 2 Chiovato L, Pinchera L. Stressful life events and Graves’ disease. Eur J Endocrinol 1996; 134: 680-682
    CrossrefPubMedGoogle Scholar
  • 3 Köhrle J. Selenium and the thyroid. Curr Opin Endocrinol Diabetes Obes 2015; 22: 392-401
    CrossrefPubMedGoogle Scholar
  • 4 Bülow Pedersen I, Knudsen N, Carlé A, Schomburg L, Köhrle J, Jørgensen T, Rasmussen LB, Ovesen L, Laurberg P. Serum selenium is low in newly diagnosed Graves’ disease: A population-based study. Clin Endocrinol (Oxf) 2013; 79: 584-590
    CrossrefPubMedGoogle Scholar
  • 5 Wertenbruch T, Willenberg HS, Sagert C, Nguyen TB, Bahlo M, Feldkamp J, Groeger C, Hermsen D, Scherbaum WA, Schott M. Serum selenium levels in patients with remission and relapse of Graves’ disease. Med Chem 2007; 3: 281-284
    CrossrefPubMedGoogle Scholar
  • 6 Wang L, Wang B, Chen SR, Hou X, Wang XF, Zhao SH, Song JQ, Wang YG. Effect of selenium supplementation on recurrent hyperthyroidism caused by Graves’ disease: A prospective pilot study. Horm Metab Res 2016; 48: 559-564
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 7 Dehina N, Hofmann PJ, Behrends T, Eckstein A, Schomburg L. Lack of association between selenium status and disease severity and activity in patients with Graves’ ophthalmopathy. Eur Thyroid J 2016; 5: 57-64
    PubMedGoogle Scholar
  • 8 Khong JJ, Goldstein RF, Sanders KM, Schneider H, Pope J, Burdon KP, Craig JE, Ebeling PR. Serum selenium status in Graves’ disease with and without orbitopathy: A case-control study. Clin Endocrinol (Oxf) 2014; 80: 905-910
    CrossrefPubMedGoogle Scholar
  • 9 Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W. European Group on Graves’ Orbitopathy . Selenium and the course of mild Graves’ orbitopathy. N Engl J Med 2011; 364: 1920-1931
    CrossrefPubMedGoogle Scholar
  • 10 Drutel A, Archambeaud F, Caron P. Selenium and the thyroid gland: more good news for clinicians. Clin Endocrinol (Oxf) 2013; 78: 155-164
    CrossrefPubMedGoogle Scholar
  • 11 Gärtner R, Duntas LH. Effects of selenium supplementation on TPOAb and cytokines in acute autoimmune thyroiditis. Thyroid 2008; 18: 669-670
    CrossrefPubMedGoogle Scholar
  • 12 Esposito D, Rotondi M, Accardo G, Vallone G, Conzo G, Docimo G, Selvaggi F, Cappelli C, Chiovato L, Giugliano D, Pasquali D. Influence of short-term selenium supplementation on the natural course of Hashimoto's thyroiditis: clinical results of a blinded placebo-controlled randomized prospective trial. J Endocrinol Invest 2017; 40: 83-89
    CrossrefPubMedGoogle Scholar
  • 13 Ajjan RA, Weetman AP. The pathogenesis of Hashimoto's Thyroiditis: further developments in our understanding. Horm Metab Res 2015; 47: 702-710 Duntas LH. The role of iodine and selenium in autoimmune thyroiditis. Horm Metab Res 2015; 47: 721–726
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 14 Duntas LH. The role of iodine and selenium in autoimmune thyroiditis. Horm Metab Res 2015; 47: 721-726
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 15 Negro R, Attanasio R, Grimaldi F, Marcocci C, Guglielmi R, Papini E. A 2016 Italian survey about the clinical use of selenium in thyroid disease. Eur Thyroid J 2016; 5: 164-170
    CrossrefPubMedGoogle Scholar
  • 16 Köhrle J, Gärtner R. Selenium and thyroid. Best Pract Res Clin Endocrinol Metab 2009; 23: 815-827
    CrossrefPubMedGoogle Scholar
  • 17 Rayman MP. Selenium and human health. Lancet 2012; 379: 1256-1268
    CrossrefPubMedGoogle Scholar
  • 18 Schomburg L. Selenium, selenoproteins and the thyroid gland: Interactions in health and disease. Nat Rev Endocrinol 2011; 18: 160-171
    PubMedGoogle Scholar
  • 19 Wastney ME, Combs Jr GF, Canfield WK, Taylor PR, Patterson KY, Hill AD, Moler JE, Patterson BH. A human model of selenium that integrates metabolism from selenite and selenomethionine. J Nutr 2011; 141: 708-717
    CrossrefPubMedGoogle Scholar
  • 20 Thiry C, Ruttens A, Pussemier L, Schneider YJ. An in vitro investigation of species-dependent intestinal transport of selenium and the impact of this process on selenium bioavailability. Br J Nutr 2013; 109: 2126-2234
    CrossrefPubMedGoogle Scholar
  • 21 Marshall JR, Ip C, Romano K, Fetterly G, Fakih M, Jovanovic B, Perloff M, Crowell J, Davis W, French-Christy R, Dew A, Coomes M, Bergan R. Methyl selenocysteine: Single-dose pharmacokinetics in men. Cancer Prev Res (Phila) 2011; 4: 1938-1944
    CrossrefPubMedGoogle Scholar
  • 22 Burk RF, Norsworthy BK, Hill KE, Motley AK, Byrne DW. Effects of chemical form of selenium on plasma biomarkers in a high-dose human supplementation trial. Cancer Epidemiol Biomarkers Prev 2006; 15: 804-810
    CrossrefPubMedGoogle Scholar
  • 23 Janghorbani M, Xia Y, Ha P, Whanger PD, Butler JA, Olesik JW, Daniels L. Metabolism of selenite in men with widely varying selenium status. J Am Coll Nutr 1999; 18: 462-469
    CrossrefPubMedGoogle Scholar
  • 24 Swanson CA, Patterson BH, Levander OA, Veillon C, Taylor PR, Helzlsouer KJ, McAdam PA, Zech LA. Human (74Se) selenomethionine metabolism: A kinetic model. Am J Clin Nutr 1991; 54: 917-926
    CrossrefPubMedGoogle Scholar
  • 25 Ip C, Thompson HJ, Zhu Z, Ganther HE. In vitro and in vivo studies of methylseleninic acid: Evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 2000; 60: 2882-2886
    PubMedGoogle Scholar
  • 26 Schrauzer GN. The nutritional significance, metabolism and toxicology of selenomethionine. Adv Food Nutr Res 2003; 47: 73-112
    PubMedGoogle Scholar
  • 27 Marcocci C, Bartalena L. Role of oxidative stress and selenium in Graves’ hyperthyroidism and orbitopathy. J Endocrinol Invest 2013; 36: 15-20
    PubMedGoogle Scholar
  • 28 Duntas LH. The evolving role of selenium in the treatment of Graves’ disease and ophthalmopathy. J Thyroid Res 2012; 736161
    PubMedGoogle Scholar
  • 29 Reszka E, Jablonska E, Gromadzinska J, Wasowicz W. Relevance of selenoprotein transcripts for selenium status in humans. Genes Nutr 2012; 7: 127-137
    CrossrefPubMedGoogle Scholar
  • 30 Mao J, Vanderlelie JJ, Perkins AV, Redman CW, Ahmadi KR, Rayman MP. Genetic polymorphisms that affect selenium status and response to selenium supplementation in United Kingdom pregnant women. Am J Clin Nutr 2016; 103: 100-106
    CrossrefPubMedGoogle Scholar
  • 31 Combs Jr GF, Watts JC, Jackson MI, Johnson LK, Zeng H, Scheett AJ, Uthus EO, Schomburg L, Hoeg A, Hoefig CS, Davis CD, Milner JA. Determinants of selenium status in healthy adults. Nutr J 2011; 10: 75
    CrossrefPubMedGoogle Scholar
  • 32 Kvícala J, Zamrazil V. Effect of iodine and selenium upon thyroid function. Cent Eur J Public Health 2003; 11: 107-113
    PubMedGoogle Scholar
  • 33 Duntas LH. Selenium and the thyroid: A close-knit connection. J Clin Endocrinol Metab. 2010; 95: 5180-5188
    CrossrefPubMedGoogle Scholar
  • 34 Negro R, Greco G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. J Clin Endocrinol Metab. 2007; 92: 1263-1268
    CrossrefPubMedGoogle Scholar
  • 35 Muecke R, Micke O, Schomburg L, Kisters K, Buentzel J, Huebner J, Kriz J. Selenium supplementation in radiotherapy patients: Do we need to measure selenium levels in serum or blood regularly prior radiotherapy?. Radiat Oncol 2014; 9: 289
    CrossrefPubMedGoogle Scholar
  • 36 Ehlers M, Jordan AL, Feldkamp J, Fritzen R, Quadbeck B, Haase M, Allelein S, Schmid C, Schott M. Anti-thyroperoxidase antibody levels >500 IU/ml indicate a moderately increased risk for developing hypothyroidism in autoimmune thyroiditis. Horm Metab Res 2016; 48: 623-629
    Artikel in Thieme ConnectPubMedGoogle Scholar